Winship Cancer Institute of Emory University | Strategic Alliance Partners

Sagar Lonial, MD, FACP, discusses the encouraging activity with the BCMA-targeted agent belantamab mafodotin in multiple myeloma.

William G. Blum, MD, discusses the current treatment landscape of acute myeloid leukemia.

Jean L. Koff, MD, MS, discusses systemic therapies in follicular lymphoma.

Pamela Blair Allen, MD, MSc, discusses treatment options in advanced-stage Hodgkin lymphoma.

Martha L. Arellano, MD, discusses the management of older patients with acute myeloid leukemia.

Sagar Lonial, MD, FACP, discusses the ICARIA-MM trial in patients with multiple myeloma who experience early relapse, have been heavily pretreated, or have refractory disease.

Jean L. Koff, MD, MS, highlights exciting advances made in follicular lymphoma and the promise of CAR T-cell therapies in other lymphoma subtypes.

William G. Blum, MD, discusses the introduction of novel agents into acute myeloid leukemia treatment and how this is impacting the role of molecular testing for patients.

Minimal residual disease has become an important investigational prognostic marker and risk stratification tool in acute lymphoblastic leukemia.

Ajay K. Nooka, MD, MPH, FACP, discusses the shift in induction regimens in multiple myeloma and the impact of daratumumab (Darzalex) on the space.

Sagar Lonial, MD, FACP, discusses important additions to the treatment arsenal in relapsed/refractory multiple myeloma.

Jonathon B. Cohen, MD, MS, discusses the integration of novel agents into clinical practice and the changing role of chemoimmunotherapy in chronic lymphocytic leukemia.

Jonathon B. Cohen, MD, MS, associate professor, Department of Hematology and Medical Oncology, Emory University School of Medicine, co-director, Lymphoma Program, and medical director, Infusion Services, Winship Cancer Institute of Emory University, discusses the design of the phase III ELEVATE-TN trial in chronic lymphocytic leukemia (CLL).

Jonathon B. Cohen, MD, MS, discusses fixed-duration therapy in chronic lymphocytic leukemia.

Sagar Lonial, MD, FACP, discusses treatments for patients with heavily pretreated multiple myeloma.

Jonathon B. Cohen, MD, MS, discusses the role of chemoimmunotherapy in chronic lymphocytic leukemia.

Ajay K. Nooka, MD, MPH, FACP, discusses current options for transplant-eligible and -ineligible patients with multiple myeloma.

Keerthi Gogineni, MD, MSHP, discusses the clinical implications of the phase II APT trial in HER2-positive breast cancer.

Sagar Lonial, MD, FACP, discusses the management of patients with relapsed multiple myeloma.

Nabil F. Saba, MD, FACP, discusses the potential benefit of immunotherapy in combination with radiation in head and neck cancer.

Nabil F. Saba, MD, FACP, director, Head and Neck Medical Oncology Program, Winship Cancer Institute of Emory University, and professor, Department of Hematology and Medical Oncology, Department of Otolaryngology, Emory University School of Medicine, discusses anticipated research in head and neck cancer.

In keeping up with the expanding breast cancer treatment armamentarium, we sat down with Jane L. Meisel, MD, and Aditya Bardia, MD, MPH, who shed light on emerging treatment strategies for patients with metastatic triple-negative breast cancer and discussed the optimal timing of genomic testing in women with progressive hormone receptor–positive disease.

Manali Bhave, MD, an assistant professor in the Department of Hematology and Medical Oncology at Winship Cancer Institute, Emory University School of Medicine, discusses promising anti-HER2 agents in metastatic HER2-positive breast cancer.

Nabil F. Saba, MD, FACP, director, Head and Neck Medical Oncology Program, Winship Cancer Institute of Emory University, professor, Department of Hematology and Medical Oncology, Department of Otolaryngology, Emory University School of Medicine, discusses ongoing research in head and neck cancer.

Suresh S. Ramalingam, MD, deputy director, Winship Cancer Institute of Emory University, discusses the activity of osimertinib (Tagrisso) in combination with other agents in EGFR-mutant non–small cell lung cancer (NSCLC).

Suresh A. Ramalingam, MD, discusses recent updates in EGFR-mutant non–small cell lung cancer and the next steps for osimertinib and other agents in this patient population.

Nabil F. Saba, MD, FACP, director, Head and Neck Medical Oncology Program, Winship Cancer Institute of Emory University, professor, Department of Hematology and Medical Oncology, Department of Otolaryngology, Emory University School of Medicine, discusses investigational deintensification approaches in HPV-related oropharyngeal squamous cell carcinoma.

Keerthi Gogineni, MD, MSHP, an assistant professor in the Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute, discusses de-escalation strategies in HER2-positive breast cancer.

Rathi N. Pillai, MD, discusses the basis for frontline combinations of chemotherapy and immunotherapy in advanced nonsquamous non–small cell lung cancer and questions surrounding the optimal sequence of these agents.

Conor E. Steuer, MD, discusses emerging agents in the treatment of patients with ALK- or ROS1-positive non–small cell lung cancer and the sequencing challenges that have resulted in the space.